ES2188665T3 - Procedimiento para la preparacion de fragmentos de cardiodilatina, fragmentos de cardiodilatina muy purificados y productos intermedios para su preparacion. - Google Patents

Procedimiento para la preparacion de fragmentos de cardiodilatina, fragmentos de cardiodilatina muy purificados y productos intermedios para su preparacion.

Info

Publication number
ES2188665T3
ES2188665T3 ES95921780T ES95921780T ES2188665T3 ES 2188665 T3 ES2188665 T3 ES 2188665T3 ES 95921780 T ES95921780 T ES 95921780T ES 95921780 T ES95921780 T ES 95921780T ES 2188665 T3 ES2188665 T3 ES 2188665T3
Authority
ES
Spain
Prior art keywords
fragments
preparation
cardiodylatin
purified
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95921780T
Other languages
English (en)
Inventor
Hansueli Immer
Wolf-Georg Forssmann
Knut Adermann
Christian Klessen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FORSSMANN WOLF-GEORG PROF DR MED
Original Assignee
FORSSMANN WOLF-GEORG PROF DR MED
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19513784A external-priority patent/DE19513784A1/de
Application filed by FORSSMANN WOLF-GEORG PROF DR MED filed Critical FORSSMANN WOLF-GEORG PROF DR MED
Application granted granted Critical
Publication of ES2188665T3 publication Critical patent/ES2188665T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA INVENCION TRATA DE UN PROCEDIMIENTO PARA LA OBTENCION DE FRAGMENTOS DE CARDIODILATINA, FRAGMENTOS DE CARDIODILATINA MUY PURIFICADOS Y LOS CORRESPONDIENTES PRODUCTOS INTERMEDIOS PARA LA OBTENCION DE ESTOS FRAGMENTOS. ADEMAS TRATA LA INVENCION DE FRAGMENTOS DE CARDIODILATINA MUY PURIFICADOS, QUE ESTAN LIBRES DE IMPUREZAS PEPTIDICAS Y QUE TIENEN UN UNICO MAXIMO DE MIGRACION EN LA ELECTROFORESIS CAPILAR, ASI COMO LOS CORRESPONDIENTES PROCEDIMIENTOS PARA SU OBTENCION
ES95921780T 1994-06-02 1995-05-30 Procedimiento para la preparacion de fragmentos de cardiodilatina, fragmentos de cardiodilatina muy purificados y productos intermedios para su preparacion. Expired - Lifetime ES2188665T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4420381 1994-06-02
DE19513784A DE19513784A1 (de) 1994-06-02 1995-04-10 Hochreines Urodilatin und Verfahren zu seiner Herstellung

Publications (1)

Publication Number Publication Date
ES2188665T3 true ES2188665T3 (es) 2003-07-01

Family

ID=25937342

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95921780T Expired - Lifetime ES2188665T3 (es) 1994-06-02 1995-05-30 Procedimiento para la preparacion de fragmentos de cardiodilatina, fragmentos de cardiodilatina muy purificados y productos intermedios para su preparacion.

Country Status (8)

Country Link
US (5) US5767239A (es)
EP (1) EP0763061B1 (es)
JP (2) JPH10500969A (es)
AT (1) ATE226960T1 (es)
AU (1) AU2671795A (es)
ES (1) ES2188665T3 (es)
IL (1) IL113979A0 (es)
WO (1) WO1995033769A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767239A (en) * 1994-06-02 1998-06-16 Boehringer Mannheim Gmbh Process for preparing cardiodilatin fragments; highly purified cardiodilatin fragments and intermediate products for the preparation of same
EP1118329A4 (en) * 1998-09-28 2004-12-15 Santen Pharmaceutical Co Ltd LACRYMAL SECRETION PROMOTERS OR OPHTHALMOLOGICAL DROPS CONTAINING NATRIURETIC PEPTIDES AS ACTIVE INGREDIENTS FOR TREATING KERATOCONJUNCTIVITY
UA71608C2 (en) * 1999-03-11 2004-12-15 Merck Patent Gmbh A method for producing the cyclic pentapeptide
PL2348114T3 (pl) 2004-04-21 2019-08-30 Alexion Pharmaceuticals, Inc. Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość
ATE469912T1 (de) * 2004-10-04 2010-06-15 Novetide Ltd Gegenionenaustauschverfahren für peptide
SI2510942T1 (sl) 2005-04-07 2016-01-29 Cardiorentis Ag Uporaba natriuretskega peptida za zdravljenje srčne odpovedi
DK2171053T3 (da) * 2007-07-20 2014-07-28 Mayo Foundation Natriuretiske polypeptider
EA201070766A1 (ru) * 2007-12-19 2011-02-28 ИКейАр ТЕРАПЬЮТИКС, ИНК. Стабильные при комнатной температуре лиофилизированные композиции натрийуретического пептида
EP2658979B1 (en) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
JP6108858B2 (ja) 2012-02-17 2017-04-05 株式会社半導体エネルギー研究所 ｐ型半導体材料および半導体装置
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2014115033A2 (en) 2013-01-25 2014-07-31 Cardiorentis Ltd. Methods of treating cardiovascular indications
CN103145827A (zh) * 2013-03-04 2013-06-12 吉尔生化（上海）有限公司 一种乌拉力肽的固相合成方法
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
MX389350B (es) 2014-12-05 2025-03-19 Alexion Pharma Inc Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones.
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
WO2016131943A1 (en) 2015-02-20 2016-08-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of obesity and complications arising therefrom including type 2 diabetes
KR102644116B1 (ko) 2015-08-17 2024-03-05 알렉시온 파마슈티칼스, 인코포레이티드 알칼린 포스파타제의 제조
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
CN106928342B (zh) * 2015-12-31 2020-10-16 深圳翰宇药业股份有限公司 一种乌拉立肽的制备方法
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
CA3019726A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
EP3464573A4 (en) 2016-06-06 2020-02-19 Alexion Pharmaceuticals, Inc. EFFECTS OF METALS ON THE PRODUCTION OF ALKALINE PHOSPHATASES
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
JP2020512363A (ja) 2017-03-31 2020-04-23 アレクシオン ファーマシューティカルズ， インコーポレイテッド 成人及び青年における低ホスファターゼ症（ｈｐｐ）を治療する方法
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
CN110785427B (zh) * 2018-05-30 2023-09-05 深圳翰宇药业股份有限公司 一种长链多肽的纯化方法
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
CN110845599B (zh) * 2018-08-21 2022-10-14 鲁南制药集团股份有限公司 一种多肽的制备纯化方法
JP2023504208A (ja) 2019-12-09 2023-02-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼポリペプチド及びその使用方法
WO2022029497A1 (en) 2020-08-06 2022-02-10 Ads Aiphia Development Services Ag Ularitide for use in methods of treating refractory ascites
WO2022029499A1 (en) 2020-08-06 2022-02-10 Ads Aiphia Development Services Ag Methods of treating refractory ascites
US12083169B2 (en) 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
EP4333846A1 (en) 2021-05-06 2024-03-13 Rigshospitalet Diagnosing and treating critically ill subjects

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU572173B2 (en) * 1983-08-29 1988-05-05 Institut De Recherches Cliniques De Montreal Natriuretic factors
DE3346953A1 (de) * 1983-12-24 1985-08-14 Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung
EP0180615B1 (en) * 1984-04-19 1995-04-05 Scios Nova Inc. Novel atrial natriuretic/vasodilator polypeptides
JPH0672157B2 (ja) * 1984-08-29 1994-09-14 味の素株式会社 新規ペプチド
US5057603A (en) * 1986-01-31 1991-10-15 Merck & Co., Inc. Peptides having ANF activity
WO1988006596A1 (en) * 1987-03-02 1988-09-07 Bissendorf Peptide Gmbh New cardiodilatin fragment, process for preparing same and use thereof
US5449751A (en) * 1987-03-02 1995-09-12 Pharma Bissendorf Peptide Gmbh Cardiodilatin fragment, process for preparing same and use thereof
US5204327A (en) * 1988-11-18 1993-04-20 Ashi Kasei Kogyo Kabushiki Kaisha Treatment of cerebral edema with anp pharmaceutical compositions
US5767239A (en) * 1994-06-02 1998-06-16 Boehringer Mannheim Gmbh Process for preparing cardiodilatin fragments; highly purified cardiodilatin fragments and intermediate products for the preparation of same

Also Published As

Publication number Publication date
US20060122371A1 (en) 2006-06-08
EP0763061A1 (de) 1997-03-19
AU2671795A (en) 1996-01-04
IL113979A0 (en) 1995-10-31
US5767239A (en) 1998-06-16
JPH10500969A (ja) 1998-01-27
ATE226960T1 (de) 2002-11-15
US20100317600A1 (en) 2010-12-16
EP0763061B1 (de) 2002-10-30
US20030171536A1 (en) 2003-09-11
WO1995033769A1 (de) 1995-12-14
JP4130671B2 (ja) 2008-08-06
JP2005298526A (ja) 2005-10-27
US20090240031A1 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
ES2188665T3 (es) Procedimiento para la preparacion de fragmentos de cardiodilatina, fragmentos de cardiodilatina muy purificados y productos intermedios para su preparacion.
ATE371670T1 (de) Reinigung von neurotrophinen
DK0877090T3 (da) Fremgangsmåde til produktion af L-aminosyrer
BR8407075A (pt) Processo para a preparacao de produto de proteina de soja desengordurado,saboroso,a partir da materia-prima de soja
SE9603068D0 (sv) Process for purifying a protein
DE69807962D1 (de) Verfahren zur Reinigung von rohem 1,1,1,3,3-Pentafluorpropan
ATE201203T1 (de) Chirale methylphenyloxazolidinone
FI956295A0 (fi) Menetelmä rasvapitoisten luonnontuotteiden fraktiointiin tai puhdistukseen
ATE389023T1 (de) Kontrolle der schotendehiszenz
FI952148L (fi) Geenitekninen menetelmä ja isäntä ksylitolin valmistamiseksi
ES2070855T3 (es) Metodo para purificar una proteina.
DE69531308D1 (de) Verfahren zur Herstellung von gereinigten papillomavirus Proteinen
ES2161790T3 (es) Procedimiento de separacion y de purificacion de proteinas dependientes de la vitamina k.
ITMI941969A0 (it) Processo per la purificazione di 2,6-diisopropilfenolo
NO930428D0 (no) Proteinstrukturen til plantetoksingelonin
BG102707A (bg) Нови триазолопурини, метод за тяхното получаване и тяхното приложение като лекарствени средства
DE69422467D1 (de) Fraktioniermethode für Nukleotidfragmente
DE69736180D1 (de) Behandlung von manischen erkrankungen
ES2188909T3 (es) Nuevos derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes o enfermedades relacionados con el estrogeno. os
EP0735140A3 (en) Process for secretory protein production
TW368505B (en) A process for preparing cardiodilatin fragments; highly purified cardiodilatin fragments and intermediate products for the preparation of same
DE69505347D1 (de) Verfahren zum Reinigen von alpha,beta-ungesättigten Estern
PT1001929E (pt) Processo para o fabrico de acidos 3-ciano-2,4-di-halogeno-5-fluorobenzoicos
BG98888A (en) Method for the preparation of 3-acylestratrienes and acylbezenes
FR2758137B1 (fr) Procede de purification du pentafluoroethane par distillation extractive